Acquisitions and IPOs across health and longevity.
Explore what each startup built, who acquired it, the value disclosed, and how long it took to reach an exit.
192 exits
Developed long-acting antibody medicines designed to relieve chronic itch and inflammatory skin disease.
Developed biopreservation media and cell-processing tools used in cell and gene therapy manufacturing workflows.
Developed a urine test that tracked bladder cancer DNA to monitor patients after treatment.
Developed cancer medicines that used antibodies to carry protein-degrading drugs directly into tumor cells.
Developed an oral medicine designed to work alongside standard treatment for a rare bone-marrow cancer.
Developed therapies designed to restore frataxin and treat rare neurological diseases including Friedreich ataxia.
Developed an antibody treatment for a virus that attacks the kidney in transplant patients.
Developed small-molecule medicines designed to calm the immune system in inflammatory conditions.
Built hardware and software that let clinicians record, edit, archive and review medical images during procedures, with a system widely used in ENT care.
Developed medicines that act on the immune system's regulatory cells inside tissues to treat autoimmune and inflammatory diseases.
Developed wearable biosensor patches that monitored heart rhythm and up to 11 vital signs for up to 30 days, in hospital and at home.
Developed oral medicines designed to control seizures in a rare childhood epilepsy caused by a single gene fault.
Manufactured active pharmaceutical ingredients and complex intermediates for generic and innovator drug companies.
Developed next-generation siRNA medicines for complement-mediated, rare and other diseases.
Developed an oral medicine for a rare inherited disease that leaves bones soft and easily broken.
Developed an oral medicine designed to slow vision loss in an inherited eye disease that begins in childhood.
Offered virtual digestive care combining dietitian-led programmes and clinician support through employer health plans.
Developed SIRP-targeted antibody medicines for immune-mediated diseases and cancer.